Basaglar ® (insulin glargine injection)

100 units/mL

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the Basaglar® (insulin glargine injection) dose for pediatric patients?

When transitioning pediatric patients, aged 6 to 15 years with type 1 diabetes mellitus, to Basaglar, the dosage recommendation is the same as that described for adults.

US_cFAQ_BIV075_PEDS_DOSE
US_cFAQ_BIV075_PEDS_DOSE
en-US

Basaglar Dosage for Pediatric Patients

When transitioning pediatric patients, aged 6 to 15 years with type 1 diabetes mellitus, to Basaglar® (insulin glargine injection) 100 units/mL, the dosage recommendation is the same as that described for adults. As in adults, the dosage of Basaglar must be individualized in these pediatric patients based on

  • metabolic needs, and
  • frequent monitoring of blood glucose concentrations.1

The efficacy and safety of Basaglar have not been established for the treatment of pediatric patients

  • younger than 6 years with type 1 diabetes mellitus, or
  • with type 2 diabetes mellitus.1

Reference

1Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.

Date of Last Review: April 14, 2021


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical